# Eltrombopag Olamine in Treating Thrombocytopenia in Patients With Chronic Myeloid Leukemia or Myelofibrosis Receiving Tyrosine Kinase Therapy

> **NCT01428635** · PHASE2,PHASE3 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 21 (actual)

## Conditions studied

- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Primary Myelofibrosis
- Thrombocytopenia

## Interventions

- **DRUG:** Eltrombopag Olamine

## Key facts

- **NCT ID:** NCT01428635
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-01-13
- **Primary completion:** 2022-01-03
- **Final completion:** 2022-01-03
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2023-09-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01428635

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01428635, "Eltrombopag Olamine in Treating Thrombocytopenia in Patients With Chronic Myeloid Leukemia or Myelofibrosis Receiving Tyrosine Kinase Therapy". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01428635. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*